Compile Data Set for Download or QSAR
maximum 50k data

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB (change energy unit to kcal/mol)

Found 12 hits in this display   

TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  32nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  32nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  219nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  219nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  2.63E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  2.63E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  3.30E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  3.30E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  1.93E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  1.93E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  2.00E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTGF-beta receptor type-1(Homo sapiens (Human))
The Brigham And Women'S Hospital

US Patent
LigandPNGBDBM161922(US10017516, Compound 54 | US9682983, 54)
Affinity DataIC50:  2.00E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent